ArticleJournal of thoracic disease2023
CT coronary artery calcification score as a prognostic marker in COVID-19.
Article in Journal of thoracic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Aortic valve calcification in echocardiography is a prognostic factor for short-term adverse outcomes in elderly patients with severe COVID-19: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.Journal of cellular physiology · 2024Review
- Prognostic Value of Coronary Artery Calcification in Patients with COVID-19 and Interstitial Pneumonia: A Case-Control Study.Journal of cardiovascular development and disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery calcification (CA) score has been established as a quantitative imaging biomarker to reflect arteriosclerosis and general vessel status. It is established as an important prognostic factor for coronary heart disease but also for other disease entities. Our aim was to use this imaging marker derived from computed tomography (CT) images to elucidate the prognostic relevance in patients with coronavirus disease 2019 (COVID-19). Methods: The clinical database was retrospectively screened for patients with COVID-19 between 2020 and 2022. A total of 241 patients (85 female patients, 35.3%) were included into the analysis. CA scoring was performed semiquantitatively on thoracic CT images with the established Weston score. Results: Overall, 61 patients (25.3%) of the investigated patient sample died. In survivors, the mean CA score was 2.3±3.0 and in non-survivors, it was 4.2±4.1 (P=0.002). In univariable regression analysis, CA was associated with 30-day mortality [odds ratio (OR) =1.15; 95% confidence interval (CI): 1.06-1.25, P<0.001]. These results were confirmed by the multivariable regression analysis adjusted for age and sex, the CA score predicted 30-day mortality (OR =1.28; 95% CI: 1.08-1.4, P=0.002). Conclusions: CA score is an independent risk factor in COVID-19. As CA scoring can easily be performed by the radiologist, it should be further investigated as an imaging marker in patients with COVID-19 and potentially be translated into clinical routine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.